Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization

Pediatric Allergy, Atopic Dermatitis, Food Hypersensitivity, and Desensitization

Allergic diseases represent the most prevalent group of chronic non-communicable disorders in European pediatric populations. Understanding the cellular immunopathology of epithelial barrier dysfunction, differentiating immediate IgE-mediated hypersensitivity from delayed non-IgE cellular responses, and executing structured escalation pathways in eczema and food allergy are core competencies for pediatric specialists.

---

The Atopic March: Epithelial Barrier Failure and Th2 Skewing

The atopic march describes the characteristic chronological progression of atopic manifestations during infancy and childhood. The classical sequence begins with atopic dermatitis (eczema) in early infancy, followed sequentially by IgE-mediated food allergy, allergic rhinitis, and bronchial asthma in late childhood and adolescence.

                    [Genetic Susceptibility: FLG Mutations]
                                      |
                     Stratum Corneum Barrier Breakdown
                     - Transepidermal Water Loss (TEWL)
                     - Epicutaneous Allergen Penetration
                                      |
                      Epithelial Keratinocyte Alarmins
                      - TSLP, Interleukin-33, Interleukin-25
                                      |
                     Dendritic Cell Priming & Polarization
                                      |
                      Th2 & ILC2 Lymphocyte Skewing
               +----------------------+----------------------+
               |                      |                      |
        Interleukin-4          Interleukin-5          Interleukin-31
       & Interleukin-13               |                      |
               |             Eosinophil Activation   Severe Pruritus
        B-Cell IgE Class          & Tissue Damage   ('The Itch that Rashes')
          Switching
               |
               v
     [Sequential Clinical Evolution: The Atopic March]
     1. Atopic Dermatitis (Infancy: Extensor / Cheeks)
     2. IgE Food Allergy (4-12 Months: Milk, Egg, Peanut)
     3. Allergic Rhinitis (Preschool / Early School Age)
     4. Allergic Asthma (School Age / Adolescence)

Molecular Pathogenesis

1. Epidermal Barrier Breakdown: Loss-of-function mutations in the gene encoding filaggrin (FLG) on chromosome 1q21 are the strongest known genetic predisposing factor for atopic dermatitis. Filaggrin is an essential structural protein that aggregates keratin intermediate filaments within stratum corneum corneocytes and breaks down into natural moisturizing factors (NMF), which maintain skin hydration and an acidic barrier pH ($4.5\text{–}5.5$). Filaggrin deficiency produces microscopic intercellular fissures, increased transepidermal water loss (TEWL), and enables foreign environmental allergens (house dust mite, peanut proteins, animal dander) to penetrate deep into the dermis.
2. Alarmin Release: Damaged keratinocytes release epithelial alarmins, including Thymic Stromal Lymphopoietin (TSLP), Interleukin-33 (IL-33), and Interleukin-25 (IL-25).
3. Th2 Lymphocyte Skewing: Alarmins instruct dermal dendritic cells to drive the differentiation of naive CD4+ T helper cells into Th2 lymphocytes and activate type 2 innate lymphoid cells (ILC2s). Th2 cells secrete signature type 2 cytokines:
   • IL-4 and IL-13: Drive B-lymphocyte immunoglobulin class-switching to allergen-specific IgE; downregulate filaggrin synthesis, creating a self-amplifying vicious cycle.
   • IL-5: Promotes eosinophil differentiation, activation, and mucosal recruitment.
   • IL-31: Binds neuro-receptors on cutaneous sensory nerves, triggering intractable, neurogenic pruritus ('the itch that rashes'). Scratching mechanically damages the stratum corneum further, inducing secondary bacterial colonization by Staphylococcus aureus.

---

Atopic Dermatitis (Eczema): Age-Specific Phenotypes

Atopic dermatitis presents with distinct morphological distributions that evolve as the child develops motor capabilities:

• Infantile Stage (<2 years): Characterized by acute, weeping, exudative, crusted erythematous papules and plaques. Primarily involves the facial cheeks, forehead, scalp, and the extensor surfaces of the limbs (reflecting crawling trauma). The napkin/diaper area is characteristically spared, because the occlusive, humid environment within the diaper prevents stratum corneum drying.
• Childhood Stage (2 to 12 years): Characterized by chronic, subacute, excoriated, lichenified plaques localized predominantly within flexural creases: antecubital fossae, popliteal fossae, anterior neck, flexor wrists, and ankles. Lichenification (thickening of the skin with accentuated skin markings) results from chronic repetitive scratching.
• Adolescent Stage (>12 years): Involves flexural folds, the face, retroauricular regions, neck, and hands, frequently accompanied by severe periorbital dermatitis and infraorbital Dennie-Morgan folds.

The Evidence-Based Management Ladder

[Step 4: Severe Refractory Disease]
  - Targeted Biologics: Dupilumab (anti-IL-4R-alpha, ages >=6 mo)
  - Systemic Immunosuppression: Ciclosporin, Methotrexate
  - Phototherapy (Narrowband UVB)
                   ^
                   |
[Step 3: Moderate-to-Severe Disease]
  - Potent Topical Corticosteroids (Short Burst)
  - Topical Calcineurin Inhibitors (Tacrolimus / Pimecrolimus)
  - Proactive Maintenance Therapy (Twice-Weekly TCS to Flare Sites)
                   ^
                   |
[Step 2: Mild-to-Moderate Flares]
  - Mild-to-Moderate Topical Corticosteroids (Hydrocortisone 1% on Face/Folds)
  - Treat Secondary Bacterial Impetiginization (Flucloxacillin)
                   ^
                   |
[Step 1: Universal Foundational Therapy for ALL Patients]
  - Liberal, Frequent Emollient Therapy (250 to 500 g/week in Children)
  - Apply Post-Bathing ('Soak and Seal' within 3 minutes)
  - Strict Avoidance of Soaps / Detergents (Use Soap-Free Cleansers)

1. Foundational Barrier Restoration (Emollients): The single most vital continuous intervention. Ointments (greasier, preservative-free) or thick creams must be applied liberally, smoothing down in the direction of hair growth. Pediatric guidelines recommend 250 to 500 g of emollient per week in children. Bathing should be brief in lukewarm water, using soap-free wash substitutes; emollients must be applied immediately post-bath ('soak and seal').
2. Topical Corticosteroids (TCS): First-line pharmacological therapy during active inflammatory flare-ups.
   • Potency Matching: Mild TCS (hydrocortisone 1%) for the face, eyelids, neck, and skin flexures/diaper area to avert cutaneous atrophy and telangiectasia; Moderate (clobetasone butyrate 0.05%) or Potent (betamethasone valerate 0.1%, mometasone furoate 0.1%) for lichenified trunk and extremity plaques.
   • Dosing Guide (The Fingertip Unit / FTU): One FTU is the quantity of cream or ointment expressed from a 5 mm nozzle tube from the distal skin crease to the tip of an adult index finger (approximately 0.5 g). One FTU covers an anatomical skin area equivalent to two adult handprints.
   • Proactive Maintenance: In children with frequent recurrent flares, applying a moderate-potency TCS or TCI twice weekly (weekend therapy) to previously affected quiescent sites dramatically reduces recurrence rates compared to reactive treatment alone.
3. Topical Calcineurin Inhibitors (TCI): Tacrolimus 0.03% ointment (licensed $\ge 2$ years) and Pimecrolimus 1% cream. TCIs inhibit calcineurin, blocking nuclear factor of activated T cells (NFAT) dephosphorylation and T-cell cytokine gene transcription. TCIs provide targeted anti-inflammatory efficacy without causing epidermal atrophy, skin thinning, striae, or glaucoma, rendering them the steroid-sparing agents of choice for delicate anatomical zones (face, eyelids, neck, perioral skin).
4. Systemic Targeted Biologics: Dupilumab, a fully human monoclonal antibody directed against the IL-4 receptor alpha subunit (IL-4R$\alpha$)—thereby blocking dual intracellular signaling of both IL-4 and IL-13—is approved in Europe for pediatric patients aged 6 months and older with severe, refractory atopic dermatitis.

Eczema Herpeticum (Kaposi's Varicelliform Eruption)

Eczema herpeticum is a life-threatening dermatological emergency caused by secondary dissemination of Herpes Simplex Virus (HSV-1 or HSV-2) across skin compromised by atopic dermatitis.

• Clinical Presentation: Sudden, explosive onset of painful, monomorphic, dome-shaped, clustered umbilicated vesicles that rapidly rupture to leave characteristic 'punched-out' round erosions with hemorrhagic crusts. Lesions predominate on the face and neck. The eruption is accompanied by high fever, severe malaise, irritability, and painful regional lymphadenopathy.
• Sight-Threatening Complication: Involvement of the periorbital skin carries high risk of herpetic keratoconjunctivitis, dendritic corneal ulceration, corneal scarring, and permanent blindness.
• Emergency Management: Immediate initiation of systemic Aciclovir (oral aciclovir for mild, early cases; intravenous aciclovir 10–15 mg/kg every 8 hours for severe, generalized, or ophthalmic presentations). Clinicians must never delay aciclovir while awaiting viral PCR swab results. Flucloxacillin is frequently co-administered to cover secondary S. aureus superinfection. Urgent ophthalmology consultation is mandatory if lesions are within the periorbital zone.

---

Food Hypersensitivity: IgE-Mediated versus Non-IgE-Mediated

Paediatric adverse food reactions are divided into IgE-mediated and non-IgE-mediated allergic disorders based on underlying immunopathological mechanisms:

Clinical Entities of Non-IgE-Mediated Food Allergy

1. Food Protein-Induced Allergic Proctocolitis (FPIAP): Consider this non-IgE condition in a thriving young infant with painless blood streaks and mucus in otherwise normal stools, after excluding other causes such as an anal fissure. Continue breastfeeding with a 2–4-week trial of maternal cow's-milk exclusion, or use extensively hydrolyzed formula if formula-fed, then arrange planned reintroduction to confirm the diagnosis. Consider additional food exclusion only if symptoms persist, with dietary advice. Prognosis is generally favorable: tolerance develops during infancy or early childhood, with periodic reassessment rather than a guaranteed resolution by the first birthday.
2. Food Protein-Induced Enteropathy (FPIE): Presents in infants under 9 months with chronic diarrhea, malabsorption, intermittent vomiting, villous blunting on jejunal biopsy, and significant faltering growth (failure to thrive). Commonest triggers are cow's milk and soy.
3. Food Protein-Induced Enterocolitis Syndrome (FPIES): Severe, non-IgE, cell-mediated disorder. Typically triggered by cow's milk, soy, rice, or oats. Presents with profuse, repetitive projectile vomiting commencing precisely 1 to 4 hours after ingestion, accompanied by severe lethargy, marked pallor, hypothermia, and abdominal distension. In 15% of acute episodes, severe dehydration and hypovolaemic shock supervene. Cutaneous (hives) and respiratory (wheeze) signs are absent. Severe episodes require IV isotonic crystalloid resuscitation ($20\text{ mL/kg}$, reassessing and repeating as needed); ondansetron is an adjunct from 6 months. Mild episodes may need only oral rehydration.

Major Food Allergens and Natural History

Over 90% of childhood food allergies are caused by the 'Big Eight' allergens: cow's milk, hen's egg, peanut, tree nuts (cashew, walnut, almond, hazelnut), wheat, soy, fish, and shellfish.

• High Resolution Rates (Outgrown):
  • Cow's Milk & Hen's Egg: Both frequently resolve during childhood, with variable timing. Allergy to well-cooked egg resolves in about two-thirds by age 6 years; tolerance to raw egg may develop later. Reassess each child's tolerance individually.
  • The Dietary Matrix (The Milk and Egg Ladders): Heat denatures conformational epitopes on milk and egg proteins. Up to 70% of milk- and egg-allergic children tolerate extensively heated / baked forms (e.g., muffins, cookies). Ingesting baked milk/egg accelerates immunological tolerance, allowing structured step-wise reintroduction along the validated 'Milk Ladder' or 'Egg Ladder'.
• High Persistence Rates (Lifelong):
  • Peanut, Tree Nuts, and Seafood: Unfavorable natural history. Spontaneous outgrowing occurs in fewer than 15% to 20% of children; over 80% to 85% persist into adult life with lifelong risk of severe anaphylaxis.

Diagnostic Interpretation: Sensitization versus Clinical Allergy

Skin Prick Testing (SPT) and serum allergen-specific IgE (sIgE) quantify immunological sensitization, which is NOT synonymous with clinical allergy:

• An SPT wheal diameter $\ge 3\text{ mm}$ greater than the negative saline control is technically positive.
• A positive test merely demonstrates the presence of circulating IgE capable of binding the allergen.
• Clinical allergy requires a convincing clinical history of immediate allergic symptoms upon ingestion OR a positive medical food challenge. Performing broad, unprompted screening panels in the absence of clinical symptoms is poor practice and leads to unnecessary, harmful dietary restrictions.

Peanut Oral Immunotherapy (OIT)

Oral Immunotherapy (OIT)—exemplified by standardized defatted peanut flour (Palforzia), authorised in the EU for children aged 1 to 17 years—represents an established disease-modifying intervention for IgE-mediated peanut allergy.

• Clinical Protocol: Comprises an initial escalating dose day under continuous specialist supervision in a resuscitation-equipped facility, followed by biweekly up-dosing over several months, reaching a continuous daily maintenance dose (typically 300 mg of peanut protein, equivalent to approximately one peanut kernel).
• Mechanism and Clinical Goal: OIT raises the patient's reaction threshold (clinical desensitization) during maintained treatment, reducing risk from accidental exposure; anaphylaxis can still occur.
• Critical Limitations & Risks: OIT does not cure the allergy and rarely induces unmaintained tolerance (permanent tolerance). If the patient halts daily consumption, the desensitized state is rapidly lost within days or weeks. Furthermore, OIT carries an ongoing risk of systemic allergic reactions (requiring adrenaline in up to 10–15% of patients) and predisposes to Eosinophilic Esophagitis (EoE). All patients on OIT must continue to practice dietary avoidance of unmeasured peanut products and carry two adrenaline auto-injectors at all times.